Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

ETF series: S&P Dow Jones Indices

Bell Direct
October 31, 2019

Morning Bell 30 October

Bell Direct
October 30, 2019

Morning Bell 29 October

Bell Direct
October 29, 2019

Morning Bell 28 October

Bell Direct
October 28, 2019

Morning Bell 28 October

Bell Direct
October 28, 2019

Morning Bell 25 October

Bell Direct
October 25, 2019

Morning Bell 24 October

Bell Direct
October 24, 2019

Morning Bell 23 October

Bell Direct
October 23, 2019